Pharma Mar, S.A.

Pharma Mar, S.A.

PHMMF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.3B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Pharma Mar, S.A.Pharma Mar, S.A.16.91.49%22%60.2
$6.30

Current Fair Value

91.3% downside

Overvalued by 91.3% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$1.30 Billion
Enterprise Value$1.33 Billion
Annual dividend$1.14
Dividend yield1.49%
Earnings per Share$4.3
Beta0.7
Outstanding Shares17,336,000

Return

Return on Equity22.41%ROE
Return on Assets14.28%
Return on Invested Capital12.02%

Valuation & Multiples

P/E Ratio16.93P/E Ratio
PEG-16.25PEG
Price to Sales6.05Price to Sales
Price to Book Ratio5.18Price to Book Ratio
Enterprise Value to Revenue6.07
Enterprise Value to EBIT37.41
Enterprise Value to Net Income23
Total Debt to Enterprise0.03
Debt to Equity0.18Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 29, 2026
EPS
$0.52
Est. $0.14
Revenue
$61.51 M
Est. $58.91 M

Next Earnings Call

Expected Date
March 1, 2027
EPS Estimate
$0.44
Consensus analyst estimate
Revenue Estimate
$63.05 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Pharma Mar S.A.

515 employees
CEO: Jose Maria Fernandez Sousa-Faro

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, t...